H. Schellekens and N. Casadevall, Immunogenicity of recombinant human proteins: causes and consequences, Journal of Neurology, vol.251, issue.S2, pp.4-9, 2004.
DOI : 10.1007/s00415-004-1202-9

L. Jacobs, D. Cookfair, R. Rudick, R. Herndon, G. Richert et al., Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis, Whitham RH, and the Multiple Sclerosis Collaborative Research Group (MSCRG), pp.285-294, 1996.
DOI : 10.1002/ana.410390304

R. Rudick, N. Simonian, J. Alam, M. Campion, J. Scaramucci et al., Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis, Neurology, vol.50, issue.5, pp.501266-1272, 1998.
DOI : 10.1212/WNL.50.5.1266

L. Jacobs, R. Beck, J. Simon, R. Kinkel, C. Brownscheidle et al., Intramuscular interferon beta-1a therapy initiated falling on a first demyelinating event in multiple sclerosis. CHAMPS Study Group, N Engl J Med, issue.13, pp.343898-904, 2000.

M. Clanet, E. Radue, L. Kappos, H. Hartung, R. Hohlfeld et al., A randomized, doubleblind , dose-comparison study of weekly interferon beta-1a in relapsing MS, Neurology, issue.10, pp.591507-1517, 2002.

H. Panitch, D. Goodin, G. Francis, P. Chang, P. Coyle et al., Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial, Neurology, issue.10, pp.591496-1506, 2002.

P. Sorensen, C. Ross, K. Clemmesen, K. Bendtzen, J. Frederiksen et al., Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis, The Lancet, vol.362, issue.9391, pp.3621184-1191, 2003.
DOI : 10.1016/S0140-6736(03)14541-2

S. Malucchi, A. Sala, F. Gilli, R. Bottero, D. Sapio et al., Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis, Neurology, issue.11, pp.622031-2037, 2004.

M. Freedman, G. Francis, E. Sanders, G. Rice, O. Connor et al., Randomized study of once-weekly interferon ??-1a therapy in relapsing multiple sclerosis: three-year data from the OWIMS study, Multiple Sclerosis Journal, vol.359, issue.1, pp.41-45, 2005.
DOI : 10.1016/S0140-6736(00)04725-5

H. Hartung, M. Freedman, C. Polman, G. Edan, L. Kappos et al., Interferon ??-1b-neutralizing antibodies 5 years after clinically isolated syndrome, Neurology, vol.77, issue.9, pp.77835-843, 2011.
DOI : 10.1212/WNL.0b013e31822c90d7

URL : http://hdl.handle.net/2078.1/124900

H. Hegen, M. Schleiser, D. Gneiss, F. Pauli, R. Ehling et al., Deisenhammer F: Persistency of neutralizing antibodies depends on titer and interferon-beta preparation, Mult Scler, vol.2012, issue.185, pp.610-615

D. Sato, I. Nakashima, T. Fukazawa, Y. Shimizu, Y. Tomizawa et al., Neutralizing Antibodies Are Associated with a Reduction of Interferon-^|^beta; Efficacy during the Treatment of Japanese Multiple Sclerosis Patients, The Tohoku Journal of Experimental Medicine, vol.228, issue.2, pp.85-92
DOI : 10.1620/tjem.228.85

P. Sorensen, N. Koch-henriksen, C. Ross, K. Clemmensen, and K. Bendtzen, Appearance and disappearance of neutralizing antibodies during interferon-beta therapy, Neurology, vol.65, issue.1, pp.33-39, 2005.
DOI : 10.1212/01.WNL.0000166049.51502.6A

P. Van-der-meide and H. Schellekens, Anti-cytokine autoantibodies: Epiphenomenon or critical modulators of cytokine action, Biotherapy, vol.347, issue.suppl. 1, pp.39-48, 1997.
DOI : 10.1007/BF02678216

G. Francis, G. Rice, and J. Alsop, Interferon ??-1a in MS: Results following development of neutralizing antibodies in PRISMS, Neurology, vol.65, issue.1, pp.48-55, 2005.
DOI : 10.1212/01.wnl.0000171748.48188.5b

L. Kappos, M. Clanet, M. Sandberg-wollheim, E. Radue, H. Hartung et al., Neutralizing antibodies and efficacy of interferon ??-1a: A 4-year controlled study, Neurology, vol.65, issue.1, pp.40-47, 2005.
DOI : 10.1212/01.wnl.0000171747.59767.5c

C. Polman, A. Bertolotto, F. Deisenhammer, G. Giovannoni, H. Hartung et al., Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis, The Lancet Neurology, vol.9, issue.7, pp.740-750, 2010.
DOI : 10.1016/S1474-4422(10)70103-4

P. Flachenecker, T. Kümpfel, B. Kallmann, M. Gottschalk, O. Grauer et al., Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters, Multiple Sclerosis, vol.8, issue.6, pp.523-526, 2002.
DOI : 10.1191/1352458502ms839oa

D. Boërio, J. Lefaucheur, J. Hogrel, and A. Créange, Physiopathologie et traitement de la fatigue dans la scl??rose en plaques, Revue Neurologique, vol.162, issue.3, pp.311-320, 2006.
DOI : 10.1016/S0035-3787(06)75017-2

L. Krupp, Editorial, Multiple Sclerosis Journal, vol.48, issue.4, pp.367-368, 2006.
DOI : 10.1001/archneur.61.2.201

J. Fisk, A. Pontefract, P. Ritvo, C. Archibald, and T. Murray, ABSTRACT:, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, vol.33, issue.01, pp.9-14, 1994.
DOI : 10.1016/0304-3959(85)90078-8

C. Heesen, L. Nawrath, C. Reich, N. Bauer, K. Schulz et al., Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour?, Journal of Neurology, Neurosurgery & Psychiatry, vol.77, issue.1, pp.34-39, 2006.
DOI : 10.1136/jnnp.2005.065805

P. Flachenecker, I. Bihler, F. Weber, M. Gottschalk, K. Toyka et al., Cytokine mRNA expression in patients with multiple sclerosis and fatigue, Multiple Sclerosis, vol.10, issue.2, pp.165-169, 2004.
DOI : 10.1191/1352458504ms991oa

S. Pittion-vouyovitch, M. Debouverie, F. Guillemin, N. Vandenberghe, R. Anxionnat et al., Fatigue in multiple sclerosis is related to disability, depression and quality of life, Journal of the Neurological Sciences, vol.243, issue.1-2, pp.39-45, 2006.
DOI : 10.1016/j.jns.2005.11.025

M. Debouverie, S. Pittion-vouyovitch, H. Brissart, and F. Guillemin, Physical dimension of fatigue correlated with disability change over time in patients with multiple sclerosis, Journal of Neurology, vol.63, issue.5, pp.633-636, 2008.
DOI : 10.1007/s00415-008-0761-6

C. Polman, S. Reingold, G. Edan, M. Filippi, H. Hartung et al., Diagnostic criteria for multiple sclerosis: 2005 revisions to the ???McDonald Criteria???, Annals of Neurology, vol.6, issue.6, pp.58840-846, 2005.
DOI : 10.1002/ana.20703

W. Matthews, Symptoms and signs. In McAlpine' s Multiple Sclerosis, pp.61-63, 1991.

G. Schumacher, G. Beebe, R. Kibler, L. Kurland, J. Kurtzke et al., PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS, Annals of the New York Academy of Sciences, vol.43, issue.6, pp.552-568, 1965.
DOI : 10.1111/j.1749-6632.1965.tb20235.x

M. Debouverie, S. Pittion-vouyovitch, S. Louis, and F. Guillemin, Validity of a French version of the fatigue impact scale in multiple sclerosis, Multiple Sclerosis Journal, vol.8, issue.1, pp.1026-1032, 2007.
DOI : 10.1191/1352458505ms1148oa

J. Cramer, B. Cuffel, V. Divan, A. Sabbagh, and M. Glassman, Patient satisfaction with an injection device for multiple sclerosis treatment, Acta Neurologica Scandinavica, vol.24, issue.3, pp.156-162, 2006.
DOI : 10.1016/S0149-2918(02)85131-1

S. Montgomery and M. Asberg, A new depression scale designed to be sensitive to change, The British Journal of Psychiatry, vol.134, issue.4, pp.382-389, 1979.
DOI : 10.1192/bjp.134.4.382

J. Pellet, D. Bobon, I. Mormont, F. Lang, and A. Massardier, Étude Princeps de Validation Française de la MADRS

R. Lam, R. Farrell, T. Aziz, E. Gibbs, G. Giovannoni et al., Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFN?? in multiple sclerosis patients, Journal of Immunological Methods, vol.336, issue.2, pp.113-118, 2008.
DOI : 10.1016/j.jim.2008.03.014

S. Grossberg, Y. Kawade, M. Kohase, H. Yokoyama, and N. Finter, The Neutralization of Interferons by Antibody. I. Quantitative and Theoretical Analyses of the Neutralization Reaction in Different Bioassay Systems, Journal of Interferon & Cytokine Research, vol.21, issue.9, pp.729-742, 2001.
DOI : 10.1089/107999001753124462

M. Etemadifar, M. Janghorbani, and V. Shaygannejad, Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis, Acta Neurologica Scandinavica, vol.273, issue.5, pp.283-287, 2006.
DOI : 10.1111/j.1600-0404.2006.00585.x

R. Rudick, L. Kappos, R. Kinkel, M. Clanet, J. Phillips et al., Gender effects on intramuscular interferon beta-1a in relapsing???remitting multiple sclerosis: analysis of 1406 patients, Multiple Sclerosis Journal, vol.11, issue.3, pp.353-360, 2011.
DOI : 10.1001/jama.1992.03480010072027

P. Flachenecker and H. Meissner, Fatigue in multiple sclerosis presenting as acute relapse: subjective and objective assessment, Multiple Sclerosis, vol.14, issue.2, pp.274-277, 2008.
DOI : 10.1177/1352458507082480

M. Capobianco, A. Rizzo, S. Malucchi, F. Sperli, D. Sapio et al., Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients, Neurological Sciences, vol.249, issue.S2, pp.29-227, 2008.
DOI : 10.1007/s10072-008-0945-y

D. Kos, E. Kerckhofs, G. Nagels, D. Hoogue, M. Ilsbroukx et al., Origin of Fatigue in Multiple Sclerosis: Review of the Literature, Neurorehabilitation and Neural Repair, vol.22, issue.1, pp.91-100, 2008.
DOI : 10.1177/1545968306298934

A. Andreasen, E. Stenager, and U. Dalgas, The effect of exercise therapy on fatigue in multiple sclerosis, Multiple Sclerosis Journal, vol.17, issue.9, pp.1041-1054, 2011.
DOI : 10.1177/1352458511401120